Caladrius Biosciences Inc. (NASDAQ: CLBS) fell 2.3% after announcing Dr. Kristen K. Buck’s appointment as the company’s Chief Medical Officer (CMO). Buck is joining the company from ICON plc, where she served in the position of CMO. She represented ICON’s position on major scientific, medical governance, and ethical matters and offered oversight and guidance to scientific and medical groups.
Before that, she worked at Optum Insights as an SVP and Chief of Clinical Development, leading regulatory groups and clinical operations in The Digital Research network clinical study business.
David J. Mazzo, Caladrius CEO and President, said they are pleased to welcome Buck to the company. He noted that Kristen has expansible and vast device/drug, medical, safety, and regulatory experience in various therapeutic areas, which will be instrumental in the evolution of Caladrius as the company advances and expands its clinical development initiatives and executes its vision. This is a great appointment, and in the coming weeks, CLBS is worth watching.
On Wednesday, CLBS stock moved down 2.30% at $1.28 with more than 267k shares, compared to its average volume of 419K shares. The stock has moved within a range of $1.2800 – 1.3400 after opening the trade at $1.30.